Loading...
Header Logo
Keywords
Last Name
Institution

HAGOP M KANTARJIAN

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66. PMID: 27244347.
      View in: PubMed
    2. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014 Mar; 55(3):624-7. PMID: 23937105.
      View in: PubMed
    3. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013 05 30; 368(22):2059-74. PMID: 23634996; PMCID: PMC3767041.
    4. Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SA. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):307-14. PMID: 23313069; PMCID: PMC4188388.
    5. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011 Nov 20; 29(33):4417-23. PMID: 21969499; PMCID: PMC3221524.
    6. Drummond MW, Holyoake TL. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 Oct 15; 98(8):1776-7; author reply 1777-8. PMID: 14534900.
      View in: PubMed
    7. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003 Oct 01; 102(7):2702-3; author reply 2703-4. PMID: 14504074.
      View in: PubMed
    8. Tsao AS, Kantarijian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002 Oct; 119(1):15-24. PMID: 12358949.
      View in: PubMed
    9. Germing U, Strupp C, Aivado M, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002 Jul 15; 100(2):731-2; author reply 732-3. PMID: 12123232.
      View in: PubMed
    10. Krsková-Honzátková L, Cermák J, Sajdová J, Starý J, Sedlácek P, Sieglová Z. Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2001 Jan; 25(1):45-53. PMID: 11137560.
      View in: PubMed
    11. Moravcová J, Nádvorníková S, Lukásová M, Klamová H. Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood. 1999 Nov 15; 94(10):3609-11. PMID: 10610116.
      View in: PubMed
    12. Lion T. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood. 1999 Aug 15; 94(4):1486-8. PMID: 10484639.
      View in: PubMed
    13. Spector N, Pulcheri W, Nucci M, Maiolino A. Comparing an apple to a fruit salad. J Clin Oncol. 1997 Aug; 15(8):3021-2. PMID: 9256146.
      View in: PubMed
    14. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995 Feb 15; 85(4):1083-94. PMID: 7849296.
      View in: PubMed
    15. Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30. PMID: 8083714.
      View in: PubMed
    16. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994 May 15; 83(10):3068-76. PMID: 7514051.
      View in: PubMed
    17. Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther. 1993 Dec; 4(6):821-34. PMID: 8186294.
      View in: PubMed
    18. Niesvizky R, Siegel D, Michaeli J. 2-Chlorodeoxyadenosine for multiple myeloma. Blood. 1993 Feb 01; 81(3):868-9. PMID: 7679003.
      View in: PubMed
    19. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5. PMID: 7921999.
      View in: PubMed
    20. Etkin M, Filaccio M, Ellerson D, Suh SP, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, et al. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45. PMID: 1391033.
      View in: PubMed
    21. Claxton D, Suh SP, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R, et al. Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21. PMID: 1665348.
      View in: PubMed
    22. Zander AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, Horwitz L, Cockerill K, Spitzer G, et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol. 1988 Oct; 6(10):1548-57. PMID: 3049949.
      View in: PubMed
    23. The clinical challenge of imatinib resistance in chronic myeloid leukemia. Targeted Oncology. 1:186-196.
    24. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 30:325-330.
    25. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 100:898-904.
    26. Streptococcus Bovis Septicemia and Meningitis Associated with Chronic Radiation Enterocolitis. Southern Medical Journal. 76:1-2.
    27. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leukemia and Lymphoma.
    28. Erratum. Cancer. 109:2625.
    29. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer. 61:369-372.
    30. Proceedings of the Annual Meeting of the Society of Hematologic Oncology, 2014. Clinical Lymphoma, Myeloma and Leukemia. 15:S1.
    31. Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors. Cancer Bulletin. 42:156-161.
    32. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9.
    33. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. American Journal of Hematology.
    34. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7.
    35. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Design, Development and Therapy. 233-243.
    36. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology.
    37. Biliary concentrations of moxalactam. Infection. 12:104.
    38. New agents and strategies in CLL treatment. Leukemia and Lymphoma. 5:139-142.
    39. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clinical Lymphoma, Myeloma and Leukemia. 16:152-162.
    40. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology.
    41. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractor y acute lymphoblastic leukemia. Haematologica. 101:1524-1533.
    42. Adult acute lymphocytic leukaemia. Cancer Forum. 19:290.
    43. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer.
    44. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. Oncotarget. 7:55083-55097.
    45. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    46. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 122:238-248.
    47. Erratum. Cancer Research. 64:2306.
    48. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology. 8.
    49. Time-dependent changes in mortality and transformation risk in MDS. Blood. 128:902-910.
    50. Utilization of Tc-99m macroaggregated albumin (MAA) perfusion studies in arterial infusion cancer chemotherapy. Journal of Nuclear Medicine. 23.
    51. Decitabine in myelodysplastic syndromes. Therapy. 2:835-842.
    52. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    53. Acute Lymphoblastic Leukemia. 228-243.
    54. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy. 7:13-21.
    55. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:323-334.
    56. Acute lymphoblastic leukemia (all) in the elderly - the significance of the philadelphia chromosome. Blood. 96.
    57. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    58. Hairy-cell leukemia. Cancer Bulletin. 37:88-90.
    59. Erratum. Leukemia. 26:2302.
    60. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (Cancer (2009) 115 (551-160)). Cancer. 116:3750.
    61. Introduction. Seminars in Hematology. 35:1-2.
    62. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 101:e224-e227.
    63. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer Journal. 6.
    64. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. The Lancet Oncology. 18:22-23.
    65. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma. British Journal of Haematology.
    66. Insurance denial of coverage for patients enrolled in cancer clinical trials is still a problem in the affordable care act era. Journal of Oncology Practice. 12:283-285.
    67. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research. 48:92-100.
    68. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leukemia and Lymphoma. 1-4.
    69. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia.
    70. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 102:79-84.
    71. Genetic therapy of human disease. Bone Marrow Transplantation. 15.
    72. Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology. Clinical Lymphoma, Myeloma and Leukemia. 16:S1.
    73. New tyrosine kinase inhibitors for chronic myelogenous leukemia. P and T. 31:732.
    74. Response. Blood. 114:224.
    75. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology.
    76. Chemotherapy Foundation Symposium XXVI. P and T. 33:713.
    77. Prediction of response and survival in patients with chronicphase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Blood Cancer Journal. 5.
    78. The Affordable Care Act, or Obamacare, 3 years later. Cancer. 123:25-28.
    79. Chronic Myelogenous Leukemia. 76-88.
    80. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:139-145.
    81. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. British Journal of Haematology.
    82. Chronic Myeloid Leukemia. 1944-1957.e2.
    83. Biology of Adult Myelocytic Leukemia and Myelodysplasia. 421-432.
    84. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports.
    85. Erratum. Nature Reviews Drug Discovery. 10:318.
    86. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes. Cancer.
    87. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6:30487-30499.
    88. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.
    89. Hormonal therapy in the male breast cancer advanced stages.
    90. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.
    91. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    92. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood. 128:877-880.
    93. The Chronic Leukemias. 1209-1218.
    94. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia.
    95. Drs. Kantarjian and Shah reply. New England Journal of Medicine. 363:1674-1675.
    96. Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia. Leukemia Research Reports. 3:17-20.
    97. Introduction. Seminars in Hematology. 44:1-3.
    98. Introduction. Seminars in Oncology. 34.
    99. Reply to M. Keyhani and N. Mahmoudi. Journal of Clinical Oncology. 30:220-222.
    100. Hematology/Oncology Clinics of North - America. Hematology/Oncology Clinics of North America. 15.
    101. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 126:1699-1706.
    102. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma. 56:2092-2097.
    103. The authors reply. New England Journal of Medicine. 375:2100-2101.
    104. Management of imatinib-resistant patients with chronic myeloid leukemia. Therapeutic Advances in Hematology. 4:103-117.
    105. NCCN guidelines® insights. JNCCN Journal of the National Comprehensive Cancer Network. 14:1505-1512.
    106. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
    107. A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.
    108. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. Journal of the National Cancer Institute. 108.
    109. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.
    110. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms. Cancer.
    111. Introduction. Seminars in Hematology. 36:1-2.
    112. Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML. Cancer Biology and Therapy. 5:711.
    113. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal. 5.
    114. Hypomethylating strategies in leukemia and myelodysplastic syndromes. P and T. 31:732-733.
    115. Prognostic significance of serum beta-2 microglobulin in myelodisplastic syndromes. Blood. 96.
    116. The role of local radiation in mediastinal T-cell lymphoblastic lymphoma. Blood. 96.
    117. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer.
    118. Correction regarding data on blinatumomab-associated seizures. Nature Reviews Clinical Oncology.
    119. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 100:1058-1063.
    120. Dr. Saglio and colleagues reply. New England Journal of Medicine. 363:1673-1674.
    121. Characteristics of sweet syndrome in patients with acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:358-363.
    122. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.
    123. Chronic Myelogenous Leukemia. Hematology/Oncology Clinics of North America. 18.
    124. Myelopathy following intrathecal chemotherapy in adults. Journal of Neuro-Oncology.
    125. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications. 7.
    126. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127:2742-2750.
    127. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer.
    128. ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia. American Journal of Hematology. 85:277-280.
    129. Acute lymphoblastic leukemia, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network. 13:1240-1279.
    130. Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leukemia Research. 38:91-94.
    131. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology. 172:97-110.
    132. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia.
    133. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer.
    134. Future directions in molecular and genetic therapy for Leukemias and solid tumors. Cancer Bulletin. 42:173-180.
    135. Novel therapeutic approaches for chronic myelogenous leukemia. Cancer Bulletin. 42:149-155.
    136. Role of the 340B drug discount program in recent cancer care trends. Journal of Oncology Practice. 11:303-307.
    137. Influenza B in hospitalized immunocompromised adults. Clinical Infectious Diseases. 25:376.
    138. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 100:1139-1145.
    139. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8.
    140. Phase i study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clinical Cancer Research. 21:1267-1272.
    141. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research. 48:1-5.
    142. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 128:504-507.
    143. American Society of Clinical Oncology. P and T. 33:400.
    144. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 30:649-657.
    145. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.
    146. Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. ONCOLOGY (United States). 26.
    147. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-Term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 127:303-309.
    148. Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Journal of Blood Medicine. 6:25-29.
    149. Letter to the editor [2]. Leukemia and Lymphoma. 22:186.
    150. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British Journal of Haematology. 171:471-477.
    151. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia. The Lancet Haematology. 2:e12-e20.
    152. Reply to price and value in cancer care. Cancer.
    153. Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clinical Lymphoma, Myeloma and Leukemia. 15:433-438.
    154. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies. The Lancet Haematology. 2:e339-e346.
    155. New drugs in acute myeloid leukemia. Annals of Oncology. 27:770-778.
    156. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    157. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Chemtracts. 14:733-738.
    158. Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized phase iii trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Journal of Blood Medicine. 6:25-29.
    159. Leukemias.
    160. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). American Journal of Hematology. 91:227-232.
    161. The Enright/McGlave Article Reviewed. Oncology. 11:1302-1306.
    162. Biology of Chronic and Acute Myeloid Leukemia. 371-383.
    163. Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Opinion on Orphan Drugs. 1:607-623.
    164. Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings. 91:1645-1666.
    165. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. Journal of Experimental Medicine. 213:1723-1740.
    166. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults. Blood. 127:1863-1869.
    167. Contract research organizations in oncology clinical research. Cancer.
    168. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clinical Lymphoma, Myeloma and Leukemia. 15:S85-S90.
    169. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Alimentary Pharmacology and Therapeutics. 44:1235-1241.
    170. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.
    171. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    172. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 121:3372-3379.
    173. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation.
    174. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib (Blood (2011) 118, 17 (4567-4576)). Blood. 122:2524.
    175. The role of decitabine in hematologic malignancies. Leukemia. 11.
    176. Detection and quantitation of BCR-ABL transcripts using a comprehensive quantitative rtpcr analysis system for minimal residual disease in CML patients. Blood. 96.
    177. Management of B-Cell Acute Lymphoblastic Leukemia. 22-28.
    178. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    179. Final 5-year study results of DASISION. Journal of Clinical Oncology. 34:2333-2340.
    180. In reply [6]. Journal of Clinical Oncology. 24:3813.
    181. Phase i trials using sleeping beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation. 126:3363-3376.
    182. 2-Chlorodeoxyadenosine. Cancer Bulletin. 43:253-258.
    183. Value of interphase fluorescent in situ hybridization (iFISH) studies in monitoring response to STI571 therapy in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood. 96.
    184. TP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.
    185. New tyrosine kinase inhibitors in chronic myeloid leukemia (CML). Leukemia Research. 31.
    186. Erratum. Seminars in Hematology. 42:274.
    187. The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015. American Journal of Medicine. 128:1162-1164.
    188. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. The American Journal of Medicine. 86:554-558.
    189. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica. 101:e324-e327.
    190. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia. 15:556-562.
    191. Treatment of Newly-Diagnosed AML with Idarubicin + ARA-C. Leukemia and Lymphoma. 7:121.
    192. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase. The Lancet Haematology.
    193. Emerging role of epigenetic therapy. Seminars in Hematology. 42.
    194. Hematology/Oncology Clinics of North America. Hematology/Oncology Clinics of North America. 14.
    195. The authors reply. New England Journal of Medicine. 370:577.
    196. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms. The Lancet Oncology. 18:100-111.
    197. Treatment of adolescents and young adults with acute lymphoblastic leukemia in the modern era. 225-236.
    198. Nilotinib in patients with systemic mastocytosis. Journal of Cancer Research and Clinical Oncology. 141:2047-2060.
    199. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry Part A. 87:346-356.
    200. Hormonal Therapy for Metastatic Male Breast Cancer. Archives of Internal Medicine. 143:237-240.
    201. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.
    202. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational New Drugs. 33:870-880.
    203. In Reply - Lowering the High Cost of Cancer Drugs. Mayo Clinic Proceedings. 91:401-403.
    204. Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.
    205. Unraveling Myelodysplastic Syndromes. Current Oncology Reports. 18:1-11.
    206. Decitabine for the treatment of acute myeloid leukemia. Expert Opinion on Orphan Drugs. 1:661-673.
    207. Nilotinib for the treatment of chronic myeloid leukemia after imatinib failure. American Journal of Hematology/ Oncology. 7.
    208. The incidence and impact of thrombocytopenia in myelodysplastic syndrome. Journal of Supportive Oncology. 5:74-75.
    209. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. Journal of Infection and Chemotherapy. 21:663-667.
    210. Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule [10]. Blood. 110:1083.
    211. From the guest editors. Cancer Journal. 13:355-356.
    212. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia Research. 41:43-47.
    213. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clinical Cancer Research. 21:985-994.
    214. DNA cross-linking and repair in cisplatin-resistant human tumor cells following exposure to a new cisplatin analogue, CI-973. International Journal of Oncology. 5:597-602.
    215. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer.
    216. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [2]. Blood. 108:4291-4292.
    217. Molecular biology and cytogenetics of chronic myeloid leukemia. 29-44.
    218. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22:1218-1226.
    219. Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen [2]. Blood. 110:1698-1699.
    220. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia. The Lancet Oncology. 17:612-621.
    221. The role of imatinib in the treatment of chronic myelogenous leukemia. American Journal of Cancer. 3:337-348.
    222. BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response. Molecular Cancer Therapeutics. 9:772.
    223. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma. 1-6.
    224. Standard Management of Patients with Chronic Myeloid Leukemia. 71-85.
    225. Erratum. British Journal of Haematology. 108:461.
    226. High dose (hd) chemotherapy in high risk (hr) myelodisplastic syndrome (mds). Blood. 96.
    227. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer.
    228. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Molecular Cytogenetics. 8.
    229. Erratum. Blood. 124:981.
    230. ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia. American Journal of Hematology. 85:283-286.
    231. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology. 12:293-302.
    232. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma. 56:390-394.
    233. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Therapeutic Advances in Hematology. 5:29-34.
    234. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia.
    235. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. The Lancet.
    236. Vosaroxin. Expert Opinion on Orphan Drugs. 1-8.
    237. New directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma. 6:89-95.
    238. Health care in the United States-basic human right or entitlement?. Annals of Oncology. 26:2193-2195.
    239. The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Frontiers in Oncology. 3 SEP.
    240. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia. The Lancet Haematology. 2:e118-e128.
    241. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer genetics.
    242. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 120:3494-3501.
    243. Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation. 15:114-119.
    244. Erratum. Expert Opinion on Biological Therapy. 15:915.
    245. Erratum. Clinical Cancer Research. 10:7787.
    246. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leukemia and Lymphoma. 56:1342-1345.
    247. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia. 16:616-624.
    248. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leukemia and Lymphoma. 1-4.
    249. Blood. 96.
    250. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia.
    251. Prognostic determinants in patients (PTS) with Philadelphia chromosome-negative (Ph-Ve) benign phase chronic myelogenous leukemia (CML).
    252. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 127:703-712.
    253. Dr. Verstovsek and Colleagues reply. New England Journal of Medicine. 366:2034.
    254. Targeting IL11 receptor in leukemia and lymphoma. Clinical Cancer Research. 21:3041-3051.
    255. The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. Clinical Cancer Research. 21:4561-4568.
    256. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 127:1398-1402.
    257. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis. Haematologica. 100:479-488.
    258. In vitro effects of STI571-containing drug combinations on growth of Ph-posittve myelogenous leukemia-derived cells. Blood. 96.
    259. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience. Leukemia and Lymphoma. 57:237-239.
    260. Meir Wetzler, MD. Cancer.
    261. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 101:e482-e484.
    262. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase. Leukemia.
    263. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 128:2096-2097.
    264. Acute myeloid leukemia. Expert Review of Hematology. 1-13.
    265. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. American Journal of Hematology. 91:606-616.
    266. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME). The Lancet Oncology.
    267. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
    268. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia.
    269. Leukemia in the elderly. Cancer Bulletin. 47:203-211.
    270. Cancer Genomics in Clinical Context. Trends in Cancer. 1:36-43.
    271. Chronic myeloid leukemia. Hematology. 3:263-276.
    272. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology. 92:155-160.
    273. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy. Leukemia and Lymphoma. 56:1643-1650.
    274. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 126:2491-2501.
    275. Fludarabine treatment of chronic lymphocytic leukemia and indolent lymphomas. Cancer Bulletin. 42:136-144.
    276. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. British Journal of Haematology.
    277. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer Journal. 5.
    278. Targeted therapy. Nature Reviews Clinical Oncology. 13:270-272.
    279. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 122:3336-3343.
    280. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma. 55:1451-1462.
    281. Hemophagocytic lymphohistiocytosis in adults. BBA Clinical. 7:36-40.
    282. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute Myelogenous Leukemia. Cancer Discovery. 6:1106-1117.
    283. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    284. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. American Journal of Hematology. 92:E14-E15.
    285. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    286. American Journal of Hematology. 92:E3-E4.
    287. Gene therapy. Cancer Bulletin. 45:139-145.
    288. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 8:135-143.
    KANTARJIAN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description